Cann Group teams up with Emyria to develop pharmacy grade CBD capsules

Australian medicinal cannabis firm Cann has moved quickly to maximise the benefits of its CBD Gelpell capsule technology by entering into a collaboration deal with healthcare technology firm Emyria

Read full article

Download the full news analysis

"*" indicates required fields

Corporate Email*

Company Name*

Name*

Department*

Industry*

Work Telephone*

How did you hear about us?*

Name

This field is for validation purposes and should be left unchanged.

I'm already a subscriber

Lorraine Mullaney

Senior writer

Lorraine is responsible for writing news analysis and assisting with copy-editing. Lorraine is a copywriter and editor who has written and edited words for a wide range of audiences, from local community newspapers to consumer magazines and trade websites.

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

Stay informed of any legal and market change in the sector that impacts your organisation
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

LATEST ALERTS

Cann Group teams up with Emyria to develop pharmacy grade CBD capsules

Lorraine Mullaney

Our Key Benefits

Sign up to our newsletter

LATEST ALERTS

Download the full news analysis

Login

Lorraine Mullaney

Our Key Benefits

Thanks for getting in touch with us

Sign up to our newsletter

Start your FREE trial